摘要
目的探究含奥沙利铂方案与FOLFIRI方案对Ⅳ期结直肠癌化疗疗效及预后影响的差别与K-ras基因状态的关系。方法收集2010年1月至2012年1月的118例接受含奥沙利铂方案或FOLFIRI方案化疗的Ⅳ期结直肠癌患者临床资料,统计患者的治疗有效率(ORR)、疾病控制率(DCR)、无进展生存时间(PFS)和总生存期(OS)。采用χ2检验比较各组临床因素差别和两种治疗方案的有效率及疾病控制率,采用Kaplan-Meier法比较无进展生存时间以及总生存期。结果 118例患者中,接受含奥沙利铂方案化疗的K-ras突变型患者PFS及OS较接受FOLFIRI方案化疗患者延长(P=0.048;P=0.037),ORR及DCR较接受FOLFIRI方案化疗患者无明显差别(P=0.961;P=0.931)。接受含奥沙利铂方案化疗的K-ras野生型患者ORR、DCR、PFS及OS较接受FOLFIRI方案化疗患者无明显差别(P=0.900;P=0.802;P=0.738;P=0.904)。结论采用含奥沙利铂方案一线化疗较FOLFIRI方案对K-ras突变型Ⅳ期结直肠癌患者更有优势,而对于K-ras野生型Ⅳ期结直肠癌患者,含奥沙利铂方案与FOLFIRI方案疗效及预后情况相当。
Objective To compare the efficacy and prognosis of oxaliplatin-based regimens and FOLFIRI regimen as the first-line chemotherapy for stage Ⅳ colorectal cancer patients with different K-ras statuses. Methods We collected clinical data of 118 stage Ⅳ colorectal cancer patients treated with oxaliplatin-based regimens or FOLFIRI regimen as the first-line chemotherapy from Jan. 2010 to Jan. 2012. The cumulative survival rate, objective response rate(ORR), disease control rate(DCR), progression free survival(PFS) and overall survival(OS) of the cases were calculated. Chi-square test was used to compare the differences of clinical factors, ORR and DCR between different groups. Kaplan-Meier method was used to compare the differences of PFS and OS. Results Oxaliplatin-based regimens chemotherapy prolonged PFS and OS of the K-ras mutant patients compared with FOLFIRI regimen chemotherapy(P=0.048; P=0.037). ORR and DCR of the K-ras mutant patients treated with oxaliplatin-based regimens chemotherapy were not significantly different from those with FOLFIRI regimen chemotherapy(P=0.961; P=0.931). ORR, DCR, PFS and OS of the K-ras wide type patients treated with oxaliplatin-based regimens chemotherapy were not significantly different from those with FOLFIRI regimen chemotherapy(P=0.900; P=0.802; P=0.738; P=0.904). Conclusion Oxaliplatin-based regimens as the first-line chemotherapy is more beneficial than FOLFIRI regimen as the first-line chemotherapy for K-ras mutant stage Ⅳ colorectal cancer patients; however, the efficacy and prognosis of K-ras wild type stage Ⅳ colorectal cancer patients were not significantly different between oxaliplatin-based regimens and FOLFIRI regimen chemotherapy.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2015年第3期280-284,共5页
Cancer Research on Prevention and Treatment
